Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05765877 | Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 26 | Pingping SongOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06418412 | A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC | recruiting | — | 600 | National Cancer Centre, SingaporeOTHER | 3 | Jun 12, 2025 | clinicaltrials |
| NCT06546007 |
| Rarecells Molecular Biomarkers for Early Detection of Lung Cancer(BioMolCTC) |
| recruiting |
| — |
| 50 |
| Rarecells Diagnostics SASINDUSTRY |
| 1 |
| Jun 11, 2025 |
| clinicaltrials |
| NCT07016126 | D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC | recruiting | Phase 3 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06754644 | A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | recruiting | Phase 3 | 808 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06924398 | Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC(ARMOR2501)(ARMOR2501) | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06929936 | Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC(PROTECT-1) | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06969612 | A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC | recruiting | Phase 1 | 21 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07008716 | Omitting CTV for Primary Tumor in LS-SCLC | recruiting | Phase 3 | 852 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06934499 | Tunisian Lung Cancer Study(LUNG-TUN) | recruiting | — | 1,334 | Dacima ConsultingOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06945523 | Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06988943 | Early Intervention Strategies for Lung Cancer | recruiting | N/A | 16,000 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06483295 | Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform | recruiting | N/A | 216 | Shanghai Chest HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06992583 | Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT06977074 | PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC(PROPHET) | recruiting | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04977791 | Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer | recruiting | — | 250 | Shanghai Chest HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05701787 | Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06218901 | Association of Psychological Distress in Patients With Lung Cancer(Life-Score) | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06343064 | Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI(KYLIN-1) | recruiting | Phase 1 / Phase 2 | 156 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06574347 | Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.(KYLIN-2) | recruiting | Phase 2 | 120 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06659042 | Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer | recruiting | Phase 2 | 32 | Shanghai Chest HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06975384 | The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer(Nezha) | recruiting | — | 1,270 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06968221 | Bovine Reinforcement in Stomach, Colorectal and Lung Operation | recruiting | Phase 3 | 172 | Shanghai Cingularbio Co. LtdINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06972576 | Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer | recruiting | Phase 1 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06165419 | Definitive Radiation for High-Risk Spine Metastases | recruiting | Phase 2 | 26 | Stony Brook UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06970795 | A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 180 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06967532 | Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients(TTV in NSCLC) | recruiting | — | 90 | Medical University of ViennaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06963307 | Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer(LumenDx) | recruiting | — | 300 | JaxBio LtdINDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT05631249 | Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C(CODEBREAK-IGR) | recruiting | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06962670 | Predicting Cancer Risk With Digital and Molecular Markers(PräDigt) | recruiting | N/A | 1,250 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06498986 | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06401824 | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | recruiting | Phase 2 | 25 | Maastricht University Medical CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06959173 | Organoid-guided Personalized Treatment of Pleural Effusion | recruiting | — | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 6, 2025 | clinicaltrials |
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05384873 | Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer(MURAL) | recruiting | N/A | 180 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05352035 | Multiomics Tumor Evolution Model of NSCLC | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05835570 | Integrin αvβ6-targeted PET in Malignant Tumors | recruiting | — | 200 | Zhongnan HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | recruiting | Phase 1 / Phase 2 | 110 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06718972 | A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China(CLM-tree datab) | recruiting | — | 1,000 | Guangzhou Medical UniversityOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06046495 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | recruiting | Phase 1 | 81 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06716437 | Prehabilitation for Patients Undergoing Lung Cancer Surgery(DIGI-Lung) | recruiting | N/A | 25 | University of MelbourneOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06937112 | 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis | recruiting | — | 20 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jun 12, 2025source: clinicaltrials